(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

(Check One) Form 20-F ý Form 40-F D ¨

The Company confirms that on 20 May 2025 it purchased a total of: (i) 30,755 ordinary shares of EUR 0.01 ("ordinary shares") on the US Trading Venues[1] and (ii) 0 ordinary shares on the London Trading Venues[2]; in both cases, from Goldman Sachs & Co. LLC, Goldman Sachs International or one of their affiliates, as detailed below.

http://www.rns-pdf.londonstockexchange.com/rns/4965J_1-2025-5-20.pdf

The Company confirms that on 21 May 2025 it purchased a total of: (i) 30,545 ordinary shares of EUR 0.01 ("ordinary shares") on the US Trading Venues[1] and (ii) 0 ordinary shares on the London Trading Venues[2]; in both cases, from Goldman Sachs & Co. LLC, Goldman Sachs International or one of their affiliates, as detailed below.

http://www.rns-pdf.londonstockexchange.com/rns/6882J_1-2025-5-21.pdf

The Company confirms that on 22 May 2025 it purchased a total of: (i) 30,719 ordinary shares of EUR 0.01 ("ordinary shares") on the US Trading Venues[1] and (ii) 0 ordinary shares on the London Trading Venues[2]; in both cases, from Goldman Sachs & Co. LLC, Goldman Sachs International or one of their affiliates, as detailed below.

All shares repurchased as part of the Programme have been or will be cancelled.

The first tranche of the Programme, which the Company announced on 14 February 2025 (as updated on 28 March 2025 and 2 May 2025) and which had a maximum aggregate amount for purchases of €275,000,000, will be completed today.

The second tranche of the Programme is expected to commence on 27 May 2025 and the Company has entered into an arrangement in relation to this second tranche with Goldman Sachs & Co. LLC and Goldman Sachs International, consisting of two contracts to enable the purchase of ordinary shares on both the US Trading Venues and the London Trading Venues. Share purchases will be made in accordance with the arrangement and made independently of and uninfluenced by the Company. The purpose of the Programme is to reduce the issued share capital of the Company.

The second tranche of the Programme is expected to cover the period from 27 May 2025 until 7 August 2025. The maximum aggregate amount for purchases in respect of this second tranche of the Programme will be €205,000,000, of which up to €55,000,000 will be in respect of the London Trading Venues (with purchases on the London Trading Venues expected to be completed by 31 July 2025).

Purchases pursuant to the second tranche of the Programme will be effected in accordance with (i) (in relation to purchases made on the London Trading Venues) the scope of the authority to repurchase ordinary shares "on market" conferred on the Company at the 2025 Annual General Meeting (ii) (in relation to purchases made on the US Trading Venues) the scope of the authority to repurchase ordinary shares "off market" conferred on the Company at the 2025 Annual General Meeting; (iii) (in relation to purchases made on the London Trading Venues) (EU) No 596/2014 (the Market Abuse Regulation) and the Commission Delegated Regulation (EU) 2016/1052 as applicable (both as in force in the UK, and as they form part of retained UK law as defined in the European Union (Withdrawal) Act 2018), (iv) Chapter 9 of the UK Listing Rules; and (v) applicable U.S. federal securities laws, including applicable US securities laws and anti-manipulation provisions thereof. In relation to purchases on the London Trading Venues, GS will acquire CREST depositary interests on the London Trading Venues, which will be cancelled together with the underlying shares they represent.

The maximum number of ordinary shares which may be purchased or committed to be purchased by the Company under the contracts entered into in respect of this second tranche of the Programme is 46,016,093 less such number of shares repurchased pursuant to the initial tranche of the Programme after 3 April 2025, which is the maximum number pursuant to the relevant authorities granted by shareholders at the Company's 2025 Annual General Meeting.

http://www.rns-pdf.londonstockexchange.com/rns/8816J_1-2025-5-22.pdf

This release contains statements, estimates or projections that constitute "forward-looking statements" concerning the financial condition, performance, results, guidance and outlook, dividends, consequences of mergers, acquisitions, joint ventures, divestitures, strategy and objectives of Coca-Cola Europacific Partners plc and its subsidiaries (together CCEP or the Group). Generally, the words "ambition", "target", "aim", "believe", "contemplate", "expect", "intend", "estimate", "anticipate", "project", "plan", "seek", "may", "could", "would", "should", "might", "will", "forecast", "outlook", "guidance", "possible", "potential", "predict", "objective" and similar expressions identify forward-looking statements, which generally are not historical in nature.

Forward-looking statements are subject to certain risks that could cause actual results to differ materially. Forward-looking statements are based upon various assumptions as well as CCEP's historical experience and present expectations or projections. As a result, undue reliance should not be placed on forward-looking statements, which speak only as of the date on which they are made. Factors that, in CCEP's view, could cause such actual results to differ materially from forward looking statements include, but are not limited to, those set forth in the "Risk Factors" section of CCEP's 2024 Annual Report on Form 20-F filed with the SEC on 21 March 2025 and subsequent filings.

The Company confirms that on 23 May 2025 it purchased a total of: (i) 27,685 ordinary shares of EUR 0.01 ("ordinary shares") on the US Trading Venues[1] and (ii) 0 ordinary shares on the London Trading Venues[2]; in both cases, from Goldman Sachs & Co. LLC, Goldman Sachs International or one of their affiliates, as detailed below.

The purchases form part of the Company's share buyback programme announced on 14 February 2025 (the "Programme").[3] In connection with the Programme, the Company expects to repurchase up to EUR 1 billion of ordinary shares (in aggregate).

http://www.rns-pdf.londonstockexchange.com/rns/0913K_1-2025-5-26.pdf

[3] These purchases were made pursuant to the first tranche of the Programme that the Company announced on 14 February 2025 (as updated on 28 March 2025 and 2 May 2025). As announced on 23 May 2025, the last day of purchases pursuant to this first tranche was 23 May 2025 and the second tranche of the Programme will start today.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.